Clinical Research Directory
Browse clinical research sites, groups, and studies.
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
Sponsor: University Hospital, Basel, Switzerland
Summary
The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common effects, depending on the dose administered, the personality traits of the person consuming it (set), or the environment in which psilocybin is taken (setting). Negative psychedelic effects may cause acute distress to the subject and acute anxiety has been linked to less favorable long-term outcomes in patients experimentally treated with psilocybin or similar substances for the treatment of depression. The 5-HT and oxytocin releaser 3,4-methylenedioxymethamphetamine (MDMA) reliably induces positive mood, euphoria, comfort, empathy, and feelings of trust. If administered in combination with psilocybin, MDMA may increase positive subjective drug effects including positive mood, empathy, and trust and reduce negative emotions and anxiety associated with psilocybin and overall produce a more positive over negative experience. The present study will assess subjective and autonomic effects of psilocybin alone and in combination with MDMA.
Key Details
Gender
All
Age Range
25 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-04-03
Completion Date
2026-07-01
Last Updated
2025-05-21
Healthy Volunteers
Yes
Conditions
Interventions
Psilocybin
A moderate dose of 20 mg psilocybin will be administered.
3,4-Methylenedioxymethamphetamine
A moderate dose of 100 mg MDMA will be administered.
Psilocybin placebo
Mannitol capsules instead of capsules containing psilocybin.
3,4-Methylenedioxymethamphetamine placebo
Mannitol capsules instead of capsules containing MDMA.
Locations (1)
University Hospital Basel
Basel, Switzerland